Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
Macrophage activation syndrome (MAS) is a potentially life threatening complication of chronic rheumatic diseases, particularly systemic juvenile idiopathic arthritis (JIA). A number of triggers have been related to the development of MAS, including viral infections, nonsteroidal antiinflammatory drug therapy, and gold salt injections. We describe a patient with systemic JIA who developed MAS shortly after receiving methotrexate, suggesting that this drug can be regarded as a potential trigger of MAS in children with JIA.
Ravelli
A
A
Dipartimento di Scienze Pediatriche, Università di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico S. Matteo, Italy.
Caria
M C
MC
Buratti
S
S
Malattia
C
C
Temporini
F
F
Martini
A
A
D018501:Antirheumatic Agents / Q000009:adverse effects*; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D002648:Child; D005260:Female; D006801:Humans; D008262:Macrophage Activation; D008264:Macrophages / Q000187:drug effects*; D008727:Methotrexate / Q000009:adverse effects*; D013577:Syndrome
D018501:Antirheumatic Agents; D008727:Methotrexate